Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy.
10.3779/j.issn.1009-3419.2022.102.45
- Author:
Jieqiong WU
1
;
Dunqiang REN
1
;
Huanhuan BI
2
;
Bingqian YI
1
;
Hongmei WANG
1
Author Information
1. Department of Respiratory and Critical Care Medcine, The Affiliated Hospital of Qingdao University.
2. School of Medicine Qingdao University, Qingdao 266000, China.
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
Lung neoplasms;
PD-L1;
TIGIT
- MeSH:
Humans;
Lung Neoplasms/drug therapy*;
Immunotherapy;
Thorax;
Immunologic Factors;
Receptors, Immunologic;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2022;25(11):819-827
- CountryChina
- Language:Chinese
-
Abstract:
T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is a newly discovered immune checkpoint molecule, mainly expressed on the surface of T cells and natural killer (NK) cells. By binding to cluster of differentiation 155 (CD155) and other ligands, it inhibits T cell and NK cell-mediated immune responses and affects the tumor microenvironment. Multiple preclinical studies have demonstrated that the TIGIT/CD155 pathway plays a role in a variety of solid and hematological tumors. Clinical trials investigating TIGIT inhibitors alone or in combination with programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors for lung cancer are currently underway.
.
